These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 12540064

  • 1. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
    Aggarwal R, Ghoshal UC, Naik SR.
    Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
    [Abstract] [Full Text] [Related]

  • 2. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.
    Dusheiko GM, Roberts JA.
    Hepatology; 1995 Dec; 22(6):1863-73. PubMed ID: 7489999
    [Abstract] [Full Text] [Related]

  • 3. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM, da Silva AL, Cherchiglia ML, Andrade EI, de Oliveira GL, Acurcio Fde A.
    Value Health; 2011 Dec; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Desai HG.
    Natl Med J India; 2003 Dec; 16(3):175; author reply 175-6. PubMed ID: 12929870
    [No Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Babu S.
    Natl Med J India; 2003 Dec; 16(3):175; author reply 175-6. PubMed ID: 12929872
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Nagral A.
    Natl Med J India; 2003 Dec; 16(3):175; author reply 175-6. PubMed ID: 12929871
    [No Abstract] [Full Text] [Related]

  • 7. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States.
    Brooks EA, Lacey LF, Payne SL, Miller DW.
    Am J Manag Care; 2001 Jul; 7(7):677-82. PubMed ID: 11464426
    [Abstract] [Full Text] [Related]

  • 8. [Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha].
    Buti M, Casado MA, Fosbrook L, Esteban R.
    Gastroenterol Hepatol; 1998 Apr; 21(4):161-8. PubMed ID: 9633175
    [Abstract] [Full Text] [Related]

  • 9. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
    Veldhuijzen IK, Toy M, Hahné SJ, De Wit GA, Schalm SW, de Man RA, Richardus JH.
    Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
    [Abstract] [Full Text] [Related]

  • 10. Global cost-effectiveness of cataract surgery.
    Lansingh VC, Carter MJ, Martens M.
    Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
    [Abstract] [Full Text] [Related]

  • 11. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C.
    Shiell A, Briggs A, Farrell GC.
    Med J Aust; 1994 Mar 07; 160(5):268-72. PubMed ID: 8107627
    [Abstract] [Full Text] [Related]

  • 12. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
    Sheerin IG, Green FT, Sellman JD.
    Drug Alcohol Rev; 2004 Sep 07; 23(3):261-72. PubMed ID: 15370005
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
    Karabay O, Tamer A, Tahtaci M, Vardi S, Celebi H.
    J Microbiol Immunol Infect; 2005 Aug 07; 38(4):262-6. PubMed ID: 16118673
    [Abstract] [Full Text] [Related]

  • 14. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients?
    Saab S, Ly D, Han SB, Lin RK, Rojter SE, Ghobrial RM, Busuttil RW.
    Liver Transpl; 2002 May 07; 8(5):449-57. PubMed ID: 12004345
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D, Baingana F, Kim J.
    J Ment Health Policy Econ; 2008 Sep 07; 11(3):127-33. PubMed ID: 18806302
    [Abstract] [Full Text] [Related]

  • 16. Economic consequences of HIV/AIDS in India.
    Pandav CS, Anand K, Shamanna BR, Chowdhury S, Nath LM.
    Natl Med J India; 1997 Sep 07; 10(1):27-30. PubMed ID: 9069706
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA.
    Cancer; 2004 Dec 01; 101(11):2574-83. PubMed ID: 15493042
    [Abstract] [Full Text] [Related]

  • 18. [Cost-effectiveness analysis of the treatment of chronic hepatitis C].
    Joliot E, Vanlemmens C, Kerleau M, Le Gales C, Woronoff-Lemsi MC, Flori YA, Seror V, Hrusovsky S, Monnet E, Bresson-Hadni S, Miguet JP.
    Gastroenterol Clin Biol; 1996 Dec 01; 20(11):958-67. PubMed ID: 9119185
    [Abstract] [Full Text] [Related]

  • 19. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB, Rose DN.
    Am J Med; 2005 Jan 01; 118(1):68-77. PubMed ID: 15639212
    [Abstract] [Full Text] [Related]

  • 20. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
    Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, T Kennedy P, Dusheiko G, Hill-Cawthorne G, Thomas H.
    Value Health; 2015 Sep 01; 18(6):800-9. PubMed ID: 26409607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.